Yale approves Clearmind Medicine patient recruitment for CMND-100 trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Yale approves Clearmind Medicine patient recruitment for CMND-100 trial

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

September 8, 2026 7:42 AM EDT

Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the Company or Clearmind), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (AUD), today announced that the Yale Universitys IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND100.

This approval advances the multicenter study, titled A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND100 in Healthy Volunteers and Subjects with AUDand directly... More